Metabolic health of the population: a modern view of the problem and solutions
https://doi.org/10.15829/1560-4071-2024-5896
EDN: CSYSEM
Abstract
Studying the metabolic health of population around the world is becoming a priority area of modern medicine. This is associated with an increase in the prevalence of overweight and obesity, which leads to a significant increase in related metabolic diseases, which are actually complications of obesity, primarily visceral. According to 2019 data, overweight and obesity are associated with 5 million deaths and 160 million disability-adjusted life years, more than half of which are due to cardiovascular diseases. This challenge requires the development of cardiometabolic medicine and the training of new specialists.
About the Authors
G. A. Chumakova
Altai State Medical University
Russian Federation
Russian Federation
Barnaul
T. Yu. Kuznetsova
Petrozavodsk State University
Russian Federation
Russian Federation
Petrozavodsk
M. A. Druzhilov
Petrozavodsk State University
Russian Federation
Russian Federation
Petrozavodsk
O. V. Gritsenko
Altai Regional Cardiology Dispensary
Russian Federation
Russian Federation
Barnaul
References
1. GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar M, Reitsma M, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377: 13-27. doi:10.1056/NEJMoa1614362.
2. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3793. (In Russ.). doi:10.15829/1728-8800-2023-3793.
3. GBD Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1223-49. doi:10.1016/S0140-6736(20)30752-2.
4. Cosentino F, Verma S, Ambery P, et al. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J. 2023;44:4141-56. doi:10.1093/eurheartj/ehad445.
5. Koenen M, Hill M, Cohen P, et al. Obesity, Adipose Tissue and Vascular Dysfunction.Circ Res. 2021;128(7):951-68. doi:10.1161/CIRCRESAHA.121.318093.
6. Powell-Wiley T, Poirier P, Burke L, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:984-1010. doi:10.1161/CIR.0000000000000973.
7. Chumakova GA, Kuznetsova TYu, Druzhilov MA, et al. Visceral adiposity as a global factor of cardiovascular risk. Russian Journal of Cardiology. 2018;(5):7-14. (In Russ.). doi:10.15829/1560-4071-2018-5-7-14.
8. Chumakova GA, Veselovskaya NG. Clinical significance of visceral obesity. Moscow: GEOTAR-Media, 2016. p. 200. (In Russ.). ISBN 978-5-9704-3988-3.
9. Chumakova GA, Veselovskaya NG, Gritsenko OV, et al. Metabolic syndrome: challenging and unresolved issues. Russian Journal of Cardiology. 2014;(3):63-71. (In Russ.). doi:10.15829/1560-4071-2014-3-63-71.
10. Mychka VB, Vertkin AL, Vardaev LI, et al. Experts' consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013;12(6):41-82. (In Russ.)
11. Drapkina OM, Angarsky RK, Rogozhkina EA, et al. Ultrasound-assisted assessment of visceral and subcutaneous adipose tissue thickness. Methodological guidelines. Cardiovascular Therapy and Prevention. 2023;22(3):3552. (In Russ.). doi:10.15829/1728-8800-2023-3552.
12. Garvey WT, Mechanick JI, Einhorn D. The American Association of Clinical Endocrinologists and the American College of Endocrinology. 2014 Advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014; 20(9):977-89. doi:10.4158/EP14280.PS.
13. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.). doi:10.15829/1560-4071-2023-5452.
14. Romantsova TI, Ostrovskaya EV. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of Clinical Medicine. 2015;1(1):75-86. (In Russ.). doi:10.18786/2072-0505-2015-1-75-86.
15. Shlyakhto EV, Nedogoda SV, Konradi AO, et al. The concept of novel national clinical guidelines on obesity. Russian Journal of Cardiology. 2016;(4):7-13. (In Russ.). doi:10.15829/1560-4071-2016-4-7-13.
16. Ndumele C, Rangaswami J, Chow S, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35. doi:10.1161/CIR.0000000000001184.
17. Ndumele C, Neeland I, Tuttle K, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148:1636-64. doi:10.1161/CIR.0000000000001186.
18. Rana M, Neeland I. Adipose tissue inflammation and cardiovascular disease: an update. Curr Diab Rep. 2022;22:27-37. doi:10.1007/s11892-021-01446-9.
19. Rossing P, Caramori M, Chan J, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990-9. doi:10.1016/j.kint.2022.06.013.
20. Druzhilov МA, Kuznetsova ТYu. Heterogeneity of obesity phenotypes in relation to cardiovascular risk. Cardiovascular Therapy and Prevention. 2019;18(1):161-7. (In Russ.). doi:10.15829/1728-8800-2019-1-161-167.
21. Stahl E, Dhindsa D, Lee S, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:948-63. doi:10.1016/j.jacc.2018.11.050.
22. Alexander M, Loomis A, van der Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367. doi:10.1136/bmj.l5367.
23. Drapkina OM, Korneeva ON. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424-9. (In Russ.). doi:10.20996/1819-6446-2016-12-4-424-429.
24. Wong R, Singal A. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open. 2020;3:e1920294. doi:10.1001/jamanetworkopen.2019.20294.
25. Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. doi:10.1161/ATV.0000000000000153.
26. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-25. doi:10.1016/S2213-8587(19)30084-1.
27. Kuznetsova TY, Chumakova GA, Druzhilov MA, et al. Clinical application of quantitative echocardiographic assessment of epicardial fat tissue in obesity. Russian Journal of Cardiology. 2017;(4):81-7. (In Russ.). doi:10.15829/1560-4071-2017-4-81-87.
28. Stupin JH, Arabin B. Overweight and Obesity before, during and after Pregnancy. Part 1:Pathophysiology, Molecular Biology and Epigenetic Consequences. Geburtshilfe Frauenheilkd. 2014;74(7):639-45. doi:10.1055/s-0034-1368486.
29. Langley‐Evans SC, Pearce J, Ellis S. Overweight, obesity and excessive weight gain in pregnancy as risk factors for adverse pregnancy outcomes: A narrative review. J Hum Nutr Diet. 2022;35(2):250-64. doi:10.1111/jhn.12999.
30. Tan HC, Roberts J, Catov J, et al. Mother's pre‐pregnancy BMI is an important determinant of adverse cardiometabolic risk in childhood. Pediatr Diabetes. 2015;16:419-26. doi:10.1111/pedi.12273.
31. Cagigas ML, Twigg SM, Fontana L. Ten tips for promoting cardiometabolic health and slowing cardiovascular aging. European Heart Journal. 2024;45(13):1094-7. doi:10.1093/eurheartj/ehad853.
32. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144:e472-87. doi:10.1161/CIR.0000000000001031.
33. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3:105-13. doi:10.1016/S2213-8587(14)70219-0.
34. McAllister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018;138:2774-86. doi:10.1161/CIRCULATIONAHA.118.034986.
35. Kim YG, Han KD, Choi JI, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18:128. doi:10.1186/s12933-019-0932-z.
36. Reiter-Brennan C, Cainzos-Achirica M, Soroosh G, et al. Cardiometabolic medicine — the US perspective on a new subspecialty. Cardiovasc Endocrinol Metab. 2020;9(3):70-80. doi:10.1097/XCE.0000000000000224.
37. Eckel RH, Blaham MJ. Cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine. Am J Med. 2019;7:132. doi:10.1016/j.amjmed.2019.02.027.
38. Jeong D, Kim J, Lee H, et al. Association of Cardiometabolic Multimorbidity Pattern with Dietary Factors among Adults in South Korea. Nutrients. 2020;12(9):2730. doi:10.3390/nu12092730.
39. Thomas M, Magwire M, Gosch K, et al. Cardiometabolic Center of Excellence: a novel care delivery model for secondary prevention of cardiovascular disease in Type 2 diabetes Circ Cardiovasc Qual Outcomes. 2021;14(10):e007682. doi:10.1161/CIRCOUTCOMES.120.007682.
40. Kuznetsova TYu, Druzhilov MA, Chumakova GA, et al. Strategies and methods for the correction of obesity and associated cardiovascular risk. Russian Journal of Cardiology. 2019;(4):61-7. (In Russ.). doi:10.15829/1560-4071-2019-4-61-67.
41. Petunina NA, Telnova MЕ. Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes. Diabetes mellitus. 2018;21(4):293-300. (In Russ.). doi:10.14341/DM9623.
42. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. doi:10.1056/NEJMoa1603827.
43. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44. doi:10.1056/NEJMoa1607141.
44. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57.
45. Druzhilov MA, Kuznetsova TYu. Role of SGLT2 inhibitors in the treatment of visceral obesity. Cardiovascular Therapy and Prevention. 2021;20(1):2648. (In Russ.). doi:10.15829/1728-8800-2021-2648.
46. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-99. doi:10.1001/jama.2015.9676.
47. Druzhilov MA, Kuznetsova TYu, Chumakova GA. Promising areas of pharmacotherapy for obesity. Russian Journal of Cardiology. 2021;26(3):4279. (In Russ.). doi:10.15829/1560-4071-2021-4279.
48. Arnold SV, de Lemos JA, Rosenson RS, et al.; GOULD Investigators. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019;140:618-20. doi:10.1161/CIRCULATIONAHA.119.041730.
Supplementary files
- The global overweight and obesity pandemic has led to a significant increase in related metabolic diseases, such as glucose metabolism disorders and type 2 diabetes, dyslipidemia and atherosclerotic cardiovascular diseases, hypertension, metabolic-associated fatty liver disease, renal diseases and many other.
- The metabolic health of the population is determined by the prevalence of overweight, obesity and related diseases.
- Treatment of patients with obesity and metabolic diseases presents management and professional difficulties, as it requires trained specialists in the field of cardiometabolic medicine, which goes beyond the scope of traditional training.
- Training of cardiometabolic medicine specialists and the opening of specialized centers/offices should become one of the priorities of modern medicine.
Review
For citations:
Chumakova G.A., Kuznetsova T.Yu., Druzhilov M.A., Gritsenko O.V. Metabolic health of the population: a modern view of the problem and solutions. Russian Journal of Cardiology. 2024;29(5):5896. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5896. EDN: CSYSEM
Views:
2051
Email this article 